Understanding how genetic changes affect blood disorders and fibrosis progression
Investigating High-Risk Epigenetic Modifying Alterations on JAK2VF Dependency and Fibrotic Progression in Myeloproliferative Neoplasms (MPNs)
['FUNDING_CAREER'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11096109
This study is looking at how certain genetic changes, especially the JAK2VF mutation, affect the progression of myeloproliferative neoplasms (MPNs) and how well treatments work, with the hope of finding better ways to help patients like you.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11096109 on ClinicalTrials.gov |
What this research studies
This research investigates the role of specific genetic mutations in myeloproliferative neoplasms (MPNs), which are blood disorders characterized by the overproduction of blood cells and fibrosis in the bone marrow. The study focuses on the JAK2VF mutation and its interaction with other genetic alterations that may worsen the disease and hinder treatment effectiveness. By using advanced mouse models, researchers aim to uncover how these genetic changes influence disease progression and response to therapies, potentially leading to new treatment strategies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with the JAK2VF mutation and associated genetic alterations.
Not a fit: Patients without myeloproliferative neoplasms or those whose conditions are unrelated to the JAK2VF mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with myeloproliferative neoplasms by targeting the underlying genetic mechanisms of the disease.
How similar studies have performed: Previous research has shown promising results in targeting genetic mutations in blood disorders, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DUNBAR, ANDREW JEFFREY — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: DUNBAR, ANDREW JEFFREY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.